Asian Journal of Natural Sciences (AJNS)
Vol.2, No.2, 2023: 69-80

Pharmaceutical and Biopharmaceuticals Industries: Revolutionizing Healthcare

Rehan Haider
Riggs Pharmaceuticals Department of Pharmacy The University of Karachi Pakistan
Corresponding Author: Rehan Haider rehan_haider64@yahoo.com

ARTICLEINFO

Keywords: Biopharmaceutical, Biosimilar, Drug Market, Monoclonal Antibodies, Recombinant Vaccines

Received : 5 April
Revised : 18 April
Accepted: 23 May

©2023 Haider: This is an open-access article distributed under the termsof the Creative Commons Atribusi 4.0 Internasional.

ABSTRACT

The pharmaceutical and biopharmaceuticals industries play a crucial role in revolutionizing healthcare by developing and delivering innovative medicines and therapies. These industries combine cutting-edge scientific research, advanced technologies, and rigorous regulatory processes to address a wide range of diseases and improve patients' lives. In this article, we will explore the key aspects of the pharmaceutical and biopharmaceuticals sectors and their impact on healthcare. Pharmaceuticals, a substance used in the diagnosis, treatment, or prevention of sickness and for restoring, correcting, or editing natural functions. A biopharmaceuticals (biological or biologic) comprising sugars, proteins, nucleic acids, living cells, or tissues is a medicinal product manufactured in extracted or semi-synthesized from natural sources like humans, animals, or microorganisms. Different from ordinary pills synthesized from chemical processes, we derive most biopharmaceuticals merchandise from natural processes alongside the extraction from residing buildings or the manufacturing with the resource of recombinant DNA used sciences. Transgenic organisms, especially plants, animals, or microorganisms that have been genetically modified, are doubtlessly used to produce biopharmaceuticals

INTRODUCTION

Pharmaceutical Industry: The pharmaceutical industry focuses on the discovery, development, production, and marketing of drugs that treat and prevent diseases. It encompasses various stages, including research and development, clinical trials, regulatory approval, manufacturing, and distribution. Key features of the pharmaceutical industry include:

a. Research and Development (R&D): Pharmaceutical companies invest heavily in R&D to discover new drugs and therapies. This involves identifying potential drug targets, conducting preclinical studies, and testing the efficacy and safety of compounds.

b. Clinical Trials: Rigorous clinical trials are conducted to assess the safety, efficacy, and optimal dosage of potential drugs. These trials involve human volunteers and follow strict protocols to ensure patient safety.

c. Regulatory Approval: Before a drug can be marketed, it must undergo rigorous scrutiny by regulatory agencies, such as the Food and Drug Administration (FDA) in the United States. These agencies assess the drug's safety, efficacy, and quality based on comprehensive data from clinical trials.

d. Manufacturing and Distribution: Pharmaceutical companies have sophisticated manufacturing facilities to produce drugs on a large scale. They adhere to strict quality control measures to ensure consistency and safety. Distribution networks ensure that medicines reach healthcare providers and patients efficiently.

1. Biopharmaceuticals Industry: The biopharmaceuticals industry focuses on developing medicines derived from biological sources, such as living cells or organisms. Biopharmaceuticals include therapeutic proteins, vaccines, antibodies, and gene therapies. Key aspects of the biopharmaceuticals industry include:

a. Biotechnology: Biopharmaceuticals are created through biotechnological processes that involve genetic engineering, recombinant DNA technology, and cell culture techniques. These advanced methodologies allow for the production of complex and targeted therapies.

b. Personalized Medicine: Biopharmaceuticals have paved the way for personalized medicine, tailoring treatments to an individual's genetic makeup and specific disease characteristics. This approach improves treatment efficacy and minimizes adverse effects.

c. Biosimilars: Biopharmaceuticals have also led to the development of biosimilars, which are highly similar versions of approved biologic drugs. Biosimilars provide cost-effective alternatives while maintaining comparable efficacy and safety profiles.

d. Immunotherapy and Gene Therapy: Biopharmaceuticals have revolutionized cancer treatment through immuno therapies, which harness the body's immune

system to fight cancer cells. Additionally, gene therapies hold promise for treating genetic disorders by modifying a patient's genetic material.

1. Impact on Healthcare: The pharmaceutical and biopharmaceuticals industries have had a profound impact on healthcare:

a. Disease Treatment and Prevention: These industries have introduced innovative drugs and therapies, providing effective treatments for previously un treatable conditions. Vaccines, antibiotics, and targeted therapies have significantly improved patient outcomes and reduced disease burdens.

b. Extended Lifespan: Pharmaceutical advancements have contributed to increased life expectancy by addressing chronic diseases and improving overall health outcomes.

c. Economic Growth and Job Creation: The pharmaceutical and biopharmaceuticals sectors are significant contributors to the global economy, generating employment opportunities and fostering economic growth.

d. Research and Collaboration: These industries promote scientific research and collaboration between academia, industry, and healthcare providers. This collaboration facilitates the exchange of knowledge, leading to further advancements in medical science

The European Medicines Agency (EMA) makes use of the precise period "advanced remedy medicinal merchandise (ATMPs)" to refer to human drugs that are based totally on cells, genes, or tissue engineering. Cell therapy merchandise (CTPs) are bio medicines containing cells/tissues that have been manipulated to trade their organic characteristics, and these cells/tissues can treat, prevent, or diagnose illnesses [1]. Gene remedy merchandise (GTPs) are therapeutic dealers to make genetic upgrades thru the repair, deletion, insertion, or substitution of mutated genes or site-specific changes for goal healing procedures [2]. Tissue engineering is the software of a mixture of cell, engineering, and fabric methods, and elements are introduced to improve, repair, or exchange solely phase of or complete organic tissues such as bones, cartilage, blood vessels, organs, skins, muscles, etc. It additionally entails the use of a tissue scaffold for the formation of new potential tissues for clinical functions [3, 4, 5]. A biosimilar, additionally recognized as "follow-on biologic," is a biologic scientific product that is almost equal to a replica of a special product manufactured with the resource of one-of-a-kind pharmaceutical companies. Someone extraordinarily related it to a licensed reference product, despite minor versions of clinically inactive components. There are no clinically substantial variants between the biosimilars and the reference merchandise in phrases of safety, purity, and potency. A well-known drug is the same as a brand-name drug in dosage, safety, strength, administration, quality, performance, and supposed uses. It required to take a lot of rigorous assessments to make positive

that the usual drug can substitute through the manufacturer's title drug. A traditional drug ought to include equal active pharmaceutical factors (APIs) with equal volume as the brand-name product and be set up to be bio-equivalent to the brand-name drug. The substitutability or therapeutic equivalence of accepted capsules has to be evaluated scientifically. If we evaluate a typical drug as therapeutically equal to the agency figuring out the product, it has comparable consequences and suggests no editions in distinction with the employer figuring out the product. Biosimilars, like everyday drugs, can be manufactured when the special "innovator" product's patent expires, and are formally approved variants of the true merchandise [6]. However, there are many editions between a hooked-up drug and a biosimilar Biosimilars have an equal scientific influence as well-known drugs on the other hand are completely similar to the special "innovator" capsules as means of the use of validation methods validate them. Biosimilars will no longer be equal to the reference products, now not like everyday tablets in which the APIs are equal to the references [7]. Despite this heterogeneity, all familiar pills and biosimilars have to keep a steady exceptional and high quality common overall performance at some factor in their life cycles [8 }

LITERATURE REVIEW

Therapeutic biopharmaceuticals typically embody recombinant protein therapy,antibody therapy, smartphone therapy, and gene therapy. Biopharmaceuticals are profitable for treatment or dealing with illnesses safely and effectually with the beneficial aid of demonstrating herbal pursuits and performing particular factors through the usage of the way of performing in the disease's pathophysiology. Compared with chemical drugs, biopharmaceuticals are greater tough to produce, have greater than one route of administration, and have one-of-a-kind pharmacokinetics. Their benefits are excessive selectivity and low nonspecific toxicity; dangers embody excessive expenses and the induction of anti-drug antibodies most vital to diminished efficacy or deficiency in Biosafety. We can optimize treatment thru the enhancement of dosing schedules and greater than one administrative route. It can decrease the fee thru the utilization of biosimilars.

METHODOLOGY

A vaccine is the most necessary biopharmaceuticals used for infectious sickness prevention. It commonly involves a natural agent that resembles a pathogen and is commonly made from inactivated microbes, attenuated microbes, toxoids (toxins), and or segments of floor antigens (subunits). Through vaccination, they burst of many infectious illnesses has exceptionally been diminished, such as measles, tetanus, and polio; Someone even eradicated some, such as smallpox. However, the burden of noninfectious ailments such as cancers, cardiovascular diseases, metabolic diseases, and neurodegenerative

illnesses is rather increasing. Currently, some vaccines are correctly utilized to give up cancers; for example, the human papilloma virus (HPV) vaccine has been widespread for the prevention of cervical most cancers

RESULTS AND DISCUSSION

Diagnosis

Besides scientific importance in remedy and prevention, some biopharmaceuticals can diagnose diseases; for example, monoclonal antibodies have been effectively utilized in the comparison of some cancers and infectious diseases, and higher are being developed [9, 10, 11]. Once monoclonal antibodies centered on a substance are produced, they can know this substance. They are really useful in immunohistochemistry, which detects antigens in regular tissue infections in female from Odisha checks which apprehend the substance in frozen tissue sections or cells.

Perspective and Challenge

To modern studies, revolutionary biopharmaceuticals are growing all at once and have opened new technological know-how for human therapy. Many researchers comprise in the enhancement of biopharmaceuticals and gain thrilling results. Biopharmaceuticals are promising from scientific views and regulatory perspectives. There are some challenges comprising scientific troubles and regulatory troubles we want to overcome scientific issue along with the enlarging in biotechnologies, an expanded variety of novel biopharmaceuticals are marketed and used for scientific software program applications in the world. Someone has appreciably used biopharmaceuticals for disorder control, prevention, and prognosis even though some scientific challenges are unsolved. Take vaccines and gene redress as examples to speak about:

Vaccine

Vaccination, the administration of an antigenic fabric (vaccine), is seen to be the nicest strategy for disorder control. Buildings and transport of vaccines can maximize the manageable advances for disorder prevention. The main advantages of vaccination embody prevention in enchantment and immunity for the long term; They complicate the obstacles to vaccination schedules, strict necessities for storage, and confined routes of administration [12]. Nanotechnology is a strategy to make organized a nano vaccine with the consumption and aspect results significantly decreased. Through the utility of nanoparticles, it is doable for vaccines to be managed and launched at a special location, regular at room temperature, and have replaceable routes for administration. Vaccines exceptionally primarily based definitely on nanotechnologies can also moreover overcome their barriers and end the case resulting in the enhancement of painless, safe, effective, and economical products. The integral challenges are the toxicity of nanoparticles and the

immune responses introduced with the beneficial aid of nanoparticles, even though some biodegradable and bio-compatible nanoparticles have been developed.

Biotechnologies' utilization of recombinant DNA technologies, genetic engineering, and tissue subculture embodies an enormous variety of structures to adjust living organisms for human use. New vaccines and the use of biotechnologies embellish merchandise awesomely and expand scientific aspects [13]. For example, general vaccines are used to provide up against infectious diseases, however, vaccines based totally on biotechnologies are being developed to forestall many noninfectious illnesses such as cancers, range I diabetes mellitus (T1DM), Alzheimer's disease, drug addiction, etc. In addition, it probably created therapeutic vaccines for every infectious and noninfectious illness through the utilization of the biotechnologies such as reverse volcanology, recombinant subunit vaccination, recombinant protein vaccination, DNA vaccination, and RNA vaccination. They complicate the critical undertaking of vaccination schedules. The vaccines, especially primarily based in reality on biotechnologies, are typically definitely factors of microorganisms (DNA, RNA, or protein); therefore, it is required to have greater than one dose to result in extra "booster" snapshots for full immunity

Gene Therapy

Although many CTPs have been licensed for advertising and marketing and advertising and marketing in many international locations and are considerably used for ailment treatment [1], contemporary gene treatment plans predominantly exist in imperative look-up laboratories and their scientific features are on different hands-on trials. Despite this, some GTPs have been typical by the utilization of the EMA such as Glycera (alipogene tiparvovec) in 2012, and with the aid of way of the United States Food and Drug Administration (US FDA) such as Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel) in 2017, respectively. Recently, gene redress has grown to be attainable via the advances in genetic engineering science that enabled the manipulation of the genome and the enhancement of transport equipment such as lipoids viruses [14], nanoparticles, microorganisms [15], gene weapons [16], electroporation [17], or nano straws [18]. Therapeutic factors have to be transported to situated cells to exert a therapeutic effect. Therefore, the transport device is quintessential for drug transport to intention cells and it is very critical to pick an amazing transport machine with specificity, efficiency, safety, and economics. However, it is difficult the desire shipping equipment because of the following issues.

Specificity: Some transport tools are now no longer very particular and can also, in addition, furnish nucleic acids to non-target cells. It is quintessential to minimize the hazard of nonspecific delivery. However, the big difference

between their advantages and dangers is complex. Efficiency: Not all transport equipment is environmentally exceptional enough; some of them are low in effectiveness and a couple of rounds of transfections are needed. It is challenging to enhance and mirror consideration of their efficiency, in particular in animals and clinics.

Biosafety: Some shipping equipment is toxic, biohazardous, or even negative to ordinary cells or recipient hosts. Some transport equipment such as lipoids, viruses, bacteria, and nanoparticles might also set off vector-associated immune responses in hosts, and overcoming immune obstacles is critical [14]. It is required to affirm their protection in preliminary tests.

Economics: The lookup and improvement (R&D) of transport equipment is possibly tricky, risky, costly, and time-consuming. Researchers, funders, and producers need to have sufficient incentives to increase shipping tools. Most biotechnology corporations have little incentive to find out novel shipping equipment because of constrained income and excessive developmental risks.
In countless latest studies, encouraging development has been made to perhaps overcome the challenges of handing over GTPs in vivo [19, 20, 21, 22]
In countless latest studies, encouraging development has been made to perhaps overcome the challenges of handing over GTPs in vivo [19, 20, 21, 22]

Table 1. Challenge Strategy

Challenge	Strategy
Specificity	Discovery of a specific virus such as adeno-associated viruses (AAVs)
Efficiency	Application of a combination system such as AAVs-CRISPRs
	Combination with several factors, such as smaller Cas9 orthologues, tissue-specific minimal promoters, AAV serotypes, and different routes of administration
Biosafety	Development of novel and safe delivery tools such as lipid nanoparticles (LNPs), AAVs, and baculoviruses

Regular Issue

Biopharmaceuticals are large difficult than small molecular-weight drugs because of their herbal source, massive molecular size, structural complexity, and environmental sensitivity. Thus, it is fundamental to expect unique and distinct regulatory troubles for the research, production, medical trials, applications, and marketing and advertising and marketing and advertising of biopharmaceuticals, even though many expert insurance plan insurance policies and developmental frameworks have already been established. Take cell

telephone treatment preferences and gene therapies, and biosimilars as examples to talk about:

Cell Treatment and Gene Therapy

CTPs and GTPs have the style to be commodified because of the actuality many producers are aiming at pursuing agency interests. Commercial advertising and marketing of unsupported therapeutics make use of CTPs and GTPs is a world assignment that has validated resistance to regulatory efforts. I tried some unapproved or unproved CTPs and GTPs on victims totally from their indefinite perspectives. Some CTPs and GTPs whose medical trials or data are although incomplete is in enchantment launched on the market completely because of giant interests. A coordinated method at the countrywide and world levels headquartered on engagement, harmonization, and enforcement has to be carried out to limit the dangers associated with direct client advertising and marketing of unapproved or unproven CTPs and GTPs [23]. However, sometimes, some CTPs or GTPs have no longer alternatively achieved their efficacy validation. Alternatively, they have sufficient information to confirm their protection and estimate their efficacy. For the remedy of patients who are in serious stipulations or have unmet scientific needs, precise CTPs or GTPs can be reachable to these victims with adaptive licensing. The regulator desires to set up a conditional approval device in the guidelines with a deadline, a fast-track review, and a dialog mechanism to have victims in pressing pick to take precise CTPs GTPs as quickly as possible. CRISPRs)/Cas9 nuclease system.

Biosimilar

As a product of living organisms, biopharmaceuticals are extra difficult than small molecular-weight chemical tablets because of their sensitivity to manufacturing procedures and post translational modifications. Most facts on the manufacturing manner are no longer utterly open to the public, because it might also be proprietary or a patent. This data hole stands for an indispensable undertaking for biosimilar builders and performs an imperative position in explaining the variations in regulatory pathways. It is required to exhibit biosimilarity and guarantee that the alternate in the manufacturing system represents no consequences for security and efficacy. The extent of the exchange is normally a key indicator of the evaluation required to consider the quality. Way of regulators has addressed otherwise Biosimilarity workouts to recognize that biosimilar builders start with essential variations together with traditional media, purification processes, and formulations [24]. Therefore, it is required to make sure that the modifications no longer impact the efficacy and security of biosimilars.

Biosimilars are described and existing their economic and scientific implications in contemporary publications, regulations, and the US FDA coaching archives. It may also change some biopharmaceuticals with more cost-

effective biosimilars when they lose patent protection. However, not like familiar drugs, biosimilars are distinct from the reference merchandise in shape and function. The US Biologics Price Competition and Innovation (BPCI) Act of 2009 created an abbreviated licensure pathway to enable for the improvement and approval of biosimilars and interchangeable reference merchandise that are licensed [25, 26]. The US FDA can approve biosimilars through the abbreviated licensure pathway under the BPCI Act. Biosimilars permitted in Europe are solely composed of easy and small molecules. Complex and large-molecule biosimilars will be subjected to an extra rigorous and extended approval manner. The economic success of biopharmaceuticals remedies and their patent expiration finally result in the improvement of biosimilars. The pharmaceutical corporation has to advance complicated biosimilars that mimic the authentic "innovator" tablets and discover analytical strategies to display similarity to regulatory authorities. A remark outlines the efforts of a built-in fitness machine to make sure biosimilar accessibility and discusses the innovative challenges and future implications. Biosimilars confront regulatory challenges on plausible implications for pricing, web page of care, and pharmacy doling out practices [27]. We trust biosimilars are beneficial to the healthcare system, however, their expected advantages might also now not be understood in the close to future.

CONCLUSIONS

The pharmaceutical and biopharmaceuticals industries continue to transform healthcare by developing groundbreaking treatments, Biopharmaceuticals are very promising for disease administration and prevention because of their traits and greater than reap over familiar drugs. Many novel biopharmaceuticals are being developed and might moreover be utilized for scientific software program applications in the shut future, even though some scientific and regulatory troubles are no matter the reality that is unsolved. We expect appearing up work together with the discovery, production, applications, prospects, and challenges of biopharmaceuticals in reaping fruitful penalties and having an outstanding influence on humans. All potentialities will come relevant and we will overcome challenges in the end if we continually.

ACKNOWLEDGEMENTS

The completion of this research project would not have been possible without the contributions and support of many individuals and organizations. We are deeply grateful to all those who played a role in the success of this project I would like to thank My Mentor [Dr. Naweed Imam Syed Prof Department of Cell Biology at the University of Calgary and Dr Sadaf Ahmed Head of psychophysiology Research Lab University of Karachi their invaluable input and support throughout the research process. Their insights and expertise were instrumental in shaping the direction of this project

Declaration of Interest

I at this moment declare that :

I have no pecuniary or other personal interest, direct or indirect, in any matter that raises or may raise a conflict with my duties as a manager of my office Management

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Financial support and sponsorship.

REFERENCES

Chen YC, Cheng HF, Yeh MK. Cell treatment law in Taiwan. Cell Transplantation. 2017; 26 (3):483-492. DOI: 10.3727/096368916X693293.

Gonçalves GAR, Paiva RMA. Gene therapy: Advances, challenges, and perspectives. Einstein (Sao Paulo). 2017; 15 (3):369-375. DOI: 10.1590/S1679-45082017RB4024.

Marei MK, El Backley RM. Dental mesenchymal stem cell-based translational regenerative dentistry: from artificial to natural replacement. Frontiers in Bioengineering and Biotechnology. 2018; 6:49. DOI: 10.3389/fbioe.2018.00049.

Shoji T, Shinoka T. Tissue-engineered vascular grafts for pediatric cardiac surgery. Translational Pediatrics. 2018; 7 (2):188-195. DOI: 10.21037/tp.2018.02.01.

Stephenson M, Grayson W. Recent advances in bioreactors for cell-based therapies. F1000Res. 2018; 7:517. DOI: 10.12688/f1000research.12533.1. PII: F1000 Faculty Rev.

Nick C. The US Biosimilars Act: Challenges dealing with regulatory approval. Pharmaceutical Medicine. 2012; 26 (3):145-152. DOI: 10.1007/bf03262388.

Camacho LH, Frost CP, Abella E, Morrow PK, Whittaker S. Biosimilars 101: Considerations for U.S. oncologists. Cancer Medicine. 2014; 3 (4):889-899. DOI: 10.1002/cam4.258.

Lamanna WC, Holzmann J, Cohen HP, Guo X, Schweigler M, Stengler T, Seidl A, Schiestl M. Maintaining the regular high-quality and scientific common overall performance of biopharmaceuticals. Expert Opinion on Biological Therapy. 2018; 18 (4):369-379. DOI: 10.1080/14712598.2018.1421169.

Strati P, Jain N, O'Brien S. Chronic lymphocytic leukemia: Diagnosis and treatment. Mayo Clinic Proceedings. 2018; 93 (5):651-664. DOI: 10.1016/j. cap.2018.03.002

Marr KA, Datta K, Mehta S, Ostrander DB, Rock M, Francis J, Feldmesser M. Urine antigen detection as a useful resource to diagnose invasive aspergillosis. Clinical Infectious Diseases. 2018. DOI: 10.1093/CID/ciy326.

Phuong NH, Kwak C, Heo CK, Cho EW, Yang J, Poo H. Development and characterization of monoclonal antibodies in opposition to nucleoprotein for prognosis of influenza A virus. Journal of Microbiology and Biotechnology, 2018; 28 (5):809-815. DOI: 10.4014/jmb.1801.01002.

Chen YC, Cheng HF, Yang YC, Yeh MK. Nanotechnologies used in biomedical vaccines. In: Stanciu SG, editor. Micro and Nanotechnologies for Biotechnology. Rijeka, Croatia: InTech; 2016. pp. 85-105. DOI: 10.5772/63453.

Chen YC, Cheng HF, Yang YC, Yeh MK. Biotechnologies used in biomedical vaccines. In: Afrin F, Hemeg H, Ozbak H, editors. Vaccine. Rijeka, Croatia: InTech; 2017. pp. 97-110. DOI: 10.5772/intechopen.69547.

Das SK, Menezes ME, Bhatia S, Wang XY, Emdad L, Sarkar D, Fisher PB. Gene redress for cancer: Strategies, challenges, and successes. Journal of Cellular Physiology. 2015; 230 (2):259-271. DOI: 10.1002/jcp.24791.

Bai Y, Gong H, Li H, Vu GP, Lu S, Liu F. Oral transport of RNase P ribozymes by Salmonella inhibits viral infections in mice. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108 (8):3222-3227. DOI: 10.1073/pnas.1014975108.

Gan WB, Grutzendler J, Wong WT, Wong RO, Lichtman JW. Multi color "idealistic" labeling of the worried computing device the use of lipophilic dye combinations. Neuron. 2000; 27 (2):219-225. DOI: 10.1016/S0896-6273 (00) 00031-3

Guo W, Guo Y, Tang S, Qu H, Zhao H. Dendritic cell-Ewing's sarcoma mobile phone hybrids enhance antitumor immunity. Clinical Orthopaedics and Related Research. 2008; 466 (9):2176-2183. DOI: 10.1007/s11999-008-0348-7

Stewart MP, Sharei A, Ding X, Sahay G, Langer R, Jensen KF. In vitro and methods for intracellular delivery. Nature. 2016; 538 (7624):183-192. DOI: 10.1038/nature19764.

Oggi GS, Sasikumar S, Reddy N, Ella KKR, Rao CM, Bokara KK. Gene transport processes for mesenchymal stem cellular phone therapy: Strategies to prolong effectivity and specificity. Stem Cell Reviews. 2017; 13 (6):725-740. DOI: 10.1007/s12015-017-9760-2

Xiao Q, Min T, Ma S, Hu L, Chen H, Lu D. Intracellular science of single-strand template will expand the knock-in effectivity through combining CRISPR/Cas9 with AAV. Molecular Genetics and Genomics. 2018; 293 (4):1051-1060. DOI: 10.1007/s00438-018-1437-2

Finn JD, Smith AR, Patel MC, Shaw L, Younis MR, van Heteren J, Kirstine T, Ciullo C, Lescarbeau R, Seitzer J, Shah RR, Shah A, Line D, Growe J, Pink M, Rohde E, Wood KM, Salomon WE, Harrington WF, Dombrowski C, Strapps WR, Chang Y, Morrissey DV. A single administration of CRISPR/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing. Cell Reports. 2018; 22 (9):2227-2235. DOI: 10.1016/j. celrep.2018.02.014

Lau CH, Suh Y. In vivo genome editing in animals the utilization of AAV-CRISPR system: Applications to translational search for of the human disease. F1000Res. 2017; 6:2153. DOI: 10.12688/f1000research.11243.1

Sipp D, Caulfield T, Kaye J, Barfoot J, Blackburn C, Chan S, De Luca M, Kent A, McCafé C, Munsie M, seldom-Faulkner M, Sugarman J, van Zimmern E, Zarzeczany A, Rasko JEJ. Marketing of unproven stem cell-based interventions: A identify to action. Science Translational Medicine. 2017; 9 (397):pii: eaag0426. DOI: 10.1126/scitranslmed. aag0426

Declerck P, Farouk-Rezk M, Rudd PM. Biosimilarity versus manufacturing change: Two remarkable concepts. Pharmaceutical Research. 2016; 33 (2):261-268. DOI: 10.1007/s11095-015-1790-3

Epstein MS, Ehrenpreis ED, Kulkarni PM. FDA-Related Matters Committee of the American College of Gastroenterology. Biosimilars: The need, the challenge, the future: The FDA perspective. The American Journal of Gastroenterology. 2014; 109 (12):1856-1859. DOI: 10.1038/ajg.2014.151.

Dougherty MK, Zineh I, Christl L. Perspectives on the current day kingdom of the biosimilar regulatory pathway in the United States. Clinical Pharmacology and Therapeutics. 2018; 103 (1):36-38. DOI: 10.1002/cpt.909.

Terson J, Budlong H, Affeldt T, Skiermont K, Kyllo G, Heaton A. Biosimilar merchandise in the ultra-modern U.S. health care and regulatory landscape. Journal of Managed Care & Specialty Pharmacy. 2017; 23 (12):1255-1259. DOI: 10.18553/jmcp.2017.23.12.1255endeavor.